The Discovery of Cancer Tissue Specific Proteins in Serum: Case Studies on Prostate Cancer

Biomarker ◽  
10.5772/36944 ◽  
2012 ◽  
Author(s):  
Spiros D. ◽  
Paul A.
Keyword(s):  
Prostate Cancer ◽  
Case Studies ◽  
Cancer Tissue ◽  
Tissue Specific ◽  
Specific Proteins

A prostate cancer tissue specific spectral library for targeted proteomic analysis

PROTEOMICS ◽  
2021 ◽  
pp. 2100147
Author(s):  
Rui Sun ◽  
Mengge Lyu ◽  
Shuang Liang ◽  
Weigang Ge ◽  
Yingrui Wang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Proteomic Analysis ◽  
Cancer Tissue ◽  
Spectral Library ◽  
Tissue Specific ◽  
Prostate Cancer Tissue

scholarly journals Poly (ADP-Ribose) Polymerase 1 Protein Expression in Normal Pancreas and Pancreatic Adenocarcinoma

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Roberto Castiglione ◽  
Aldo E. Calogero ◽  
Enzo Vicari ◽  
Giovanna Calabrini ◽  
Anna Cosentino ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pancreatic Cancer ◽  
Cell Death ◽  
Pancreatic Adenocarcinoma ◽  
Cancer Tissue ◽  
Normal Pancreas ◽  
Normal Prostate ◽  
Cytoplasmic Staining ◽  
Cancer Of The Pancreas ◽  
Parp 1

Pancreatic cancer is a most frequent cancer in Europe, and the majority of cases of cancer of the pancreas are diagnosed above the age of 65. Radical surgery is the first curative treatment of pancreatic cancer, and alternative or combined therapeutic options, in particular, consist of adjuvant or neoadjuvant chemotherapy, with or without radiotherapy. Many factors, including diet and genetics, have been implicated in the development of cancer of the pancreas. Poly (ADP-ribose) polymerase 1 (PARP-1) protein is required for translocation of the apoptosis-inducing factor (AIF) from the mitochondria to the nucleus. It is involved in programmed cell death processes. Different PARP-1 gene expression proteins have been observed in various tumors such as lung, ovarian, endometrial, skin, and glioblastoma. We evaluated the expression of PARP-1 protein in pancreatic adenocarcinoma and normal pancreas tissues by immunohistochemistry. Protein PARP-1 in the nucleus was found in all samples (normal pancreas and pancreatic adenocarcinoma tissues). No cytoplasmic staining was observed in any sample. PARP-1-positive cells resulted higher in the normal pancreas compared with the pancreas with adenocarcinoma. PARP-1 overexpression in prostate cancer tissue compared with normal prostate suggests a greater activity of PARP-1 in these tumors. These findings suggest that PARP-1 expression in prostate cancer is an attempt to trigger apoptosis in this type of tumor, similarl to that reported in other cancers. This finding suggests that PARP-1-mediated cell death pathways are inhibited in this cancer.

scholarly journals Increased expression of ARF GTPases in prostate cancer tissue

SpringerPlus ◽  
2015 ◽  
Vol 4 (1) ◽  
Author(s):  
Claire Morgan ◽  
Paul D Lewis ◽  
Lynda Hopkins ◽  
Stephanie Burnell ◽  
Howard Kynaston ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Tissue ◽  
Prostate Cancer Tissue ◽  
Arf Gtpases

scholarly journals Bioorthogonal Labeling of Human Prostate Cancer Tissue Slice Cultures for Glycoproteomics

2017 ◽  
Vol 56 (31) ◽  
pp. 8992-8997 ◽  
Author(s):  
David R. Spiciarich ◽  
Rosalie Nolley ◽  
Sophia L. Maund ◽  
Sean C. Purcell ◽  
Jason Herschel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tissue Slice ◽  
Human Prostate ◽  
Cancer Tissue ◽  
Human Prostate Cancer ◽  
Bioorthogonal Labeling ◽  
Prostate Cancer Tissue

404 DEVELOPMENT OF MULTIPARAMETRIC PROGNOSTIC MODELS USING LARGE PROSTATE CANCER TISSUE MICROARRAYS

2011 ◽  
Vol 10 (2) ◽  
pp. 141
Author(s):  
S. Minner ◽  
M.C. Tsourlakis ◽  
J. Müller ◽  
L. Burkhardt ◽  
P. Tennstedt ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tissue Microarrays ◽  
Prognostic Models ◽  
Cancer Tissue ◽  
Prostate Cancer Tissue ◽  
Large Prostate

Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 25-25
Author(s):  
Hanna Tukachinsky ◽  
Russell Madison ◽  
Jon Chung ◽  
Lucas Dennis ◽  
Bernard Fendler ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Advanced Prostate Cancer ◽  
Acquired Resistance ◽  
Genomic Analysis ◽  
Circulating Tumor Dna ◽  
Resistance Mechanisms ◽  
Cancer Tissue ◽  
Castration Resistant Prostate Cancer ◽  
High Level ◽  
Tumor Dna

25 Background: Comprehensive genomic profiling (CGP) by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) from plasma provides a minimally invasive method to identify targetable genomic alterations (GAs) and resistance mechanisms in patients with metastatic castration-resistant prostate cancer (mCRPC). The circulating tumor fraction in patients with mCRPC and the clinical validity of GAs detected in plasma remain unknown. We evaluated the landscape of GAs using ctDNA-based CGP and assessed concordance with tissue-based CGP. Methods: Plasma from 3,334 patients with advanced prostate cancer (including 1,674 mCRPC screening samples from the TRITON2/3 trials and 1,660 samples from routine clinical CGP) was analyzed using hybrid-capture-based gene panel NGS assays. Results were compared with CGP of 2,006 metastatic prostate cancer tissue biopsies. Concordance was evaluated in 837 patients with both tissue (archival or contemporaneous) and plasma NGS results. Results: 3,127 patients [94%] had detectable ctDNA. BRCA1/2 were mutated in 295 patients [8.8%]. In concordance analysis, 72/837 [8.6%] patients had BRCA1/2 mutations detected in tissue, 67 [93%] of whom were also identified by ctDNA, and 20 patients were identified using ctDNA but not tissue [23% of all patients identified using ctDNA]. ctDNA detected subclonal BRCA1/2 reversions in 10 of 1,660 [0.6%] routine clinical CGP samples. AR alterations, including amplifications and hotspot mutations, which were detected in 940/2,213 patients [42%]. Rare AR compound mutations, rearrangements, and novel in-frame deletions were identified. Altered pathways included PI3K/AKT/mTOR [14%], WNT/β-catenin [17%], and RAS/RAF/MEK [5%]. Microsatellite instability was detected in 31/2,213 patients [1.4%]. Conclusions: In the largest study of mCRPC plasma samples conducted to date, CGP of ctDNA recapitulated the genomic landscape detected in tissue biopsies, with a high level of agreement in detection of BRCA1/2 alterations. It also identified patients who may have gained somatic BRCA1/2 alterations since archival tissue was collected. ctDNA detected more acquired resistance GAs than tissue, including novel AR-activating variants. The large percentage of patients with rich genomic signal from ctDNA, and the sensitive, specific detection of BRCA1/2 alterations position liquid biopsy as a compelling clinical complement to tissue CGP for patients with mCRPC.

Sign in / Sign up

Export Citation Format

Share Document